Suppr超能文献

荷兰队列中法布里病患者酶替代疗法的停用情况。

Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort.

作者信息

Arends Maarten, Linthorst Gabor E, Hollak Carla E, Biegstraaten Marieke

机构信息

Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, PO Box 22660, Amsterdam 1100 DD, The Netherlands.

出版信息

Mol Genet Metab. 2016 Feb;117(2):194-8. doi: 10.1016/j.ymgme.2015.11.014. Epub 2015 Dec 1.

Abstract

Fabry disease (FD) is a progressive, multi-organ, lysosomal storage disease. Enzyme replacement therapy (ERT) is available for the treatment of the disease. While the reasons to initiate ERT have been frequently discussed, discontinuation of ERT is rarely reported. In this paper we describe our experiences with stopping ERT in FD. From 1999 through 2015, twenty-one patients discontinued ERT. These patients were generally older and more severely affected in comparison those who continued ERT. The reason to discontinue ERT switched from death or terminal illness in the first years towards treatment failure in more recent years. Three cases are described in more detail. We conclude that discontinuation of ERT should or may be considered in subgroups of FD patients although further studies on the effectiveness of ERT in subgroups of patients and the course of the disease after discontinuation of ERT are needed.

摘要

法布里病(FD)是一种进行性、多器官的溶酶体贮积病。酶替代疗法(ERT)可用于治疗该疾病。虽然启动ERT的原因已被频繁讨论,但ERT的停药情况却鲜有报道。在本文中,我们描述了我们在FD患者中停用ERT的经验。从1999年到2015年,有21名患者停用了ERT。与继续接受ERT治疗的患者相比,这些患者通常年龄更大,病情更严重。停用ERT的原因从最初几年的死亡或晚期疾病转变为近年来的治疗失败。详细描述了3个病例。我们得出结论,尽管需要对ERT在亚组患者中的有效性以及停药后疾病进程进行进一步研究,但在FD患者亚组中应该或可以考虑停用ERT。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验